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Abstract
Background: Antibody production after allogeneic administration of mesenchymal stem cells (MSCs) could impact
their clinical application. Proinflammatory priming of MSCs can potentiate their regulatory ability in vivo but increased
expression of major histocompatibility complex (MHC) might augment their immunogenicity, potentially leading to
immune memory thus limiting repeated allogeneic administration. This study aimed at evaluating the production of
cytotoxic allo-antibodies directed against donor’s ELA (equine leukocyte antigen) in mismatched and halfmatched
horses receiving repeated intraarticular administration of stimulated MSCs (MSC-primed) and unstimulated
MSCs (MSC-naïve) in pathologic joints.
Methods: From available stored samples from a previous in vivo study, cells from one donor and serially
collected sera (five time-points) from three groups of recipients were used based on their ELA haplotypes to
perform microcytotoxicity assays: Group 1 recipients mismatched with the donor that received MSC-naïve
(naïve-mismatched recipients); Group 2 recipients mismatched with the donor that received MSC-primed
(primed-mismatched recipients); Group 3 recipients halfmatched with the donor (sharing 1/2 haplotypes) that
received MSC-primed (primed-halfmatched recipients). Sera from recipients (neat, 1:2 and 1:16 dilution) were
tested against target cells from the donor (cryopreserved and expanded MSC-naïve and MSC-primed) or from
one animal presenting the same ELA haplotypes than the donor (fresh peripheral blood lymphocytes as control).
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Results: One to three weeks after first MSC administration, all recipient groups produced allo-antibodies regardless of
MSC received (naïve or primed) and matching degree with donor. However, secondary response after MSC re-exposure
was less evident in halfmatched recipients (MSC-primed) than in mismatched ones (both MSC-naïve and MSC-primed).
Recipients of MSC-primed (both mismatched and halfmatched) tended towards developing lower antibody response
than MSC-naïve recipients in vivo, but MSC-primed were targeted to death in higher percentage in vitro in the
microcytoxicity assay.
Conclusions: After first intraarticular allogeneic administration, the immunomodulatory profile of MSC-primed would
have led to lower antibody production, but these antibodies would target more easily MSC-primed after second
injection (re-exposure), likely because of their higher MHC expression.
Keywords: Allogeneic, Immunogenicity, Joint, Horse, Humoral response, MSC priming, Major histocompatibility
complex (MHC)
Background
The role of the horse as a sportive animal requires the
proper function of its musculoskeletal system. Tendon,
ligament or joint injuries represent about 80% of the
causes of diminished performance with important direct
and indirect economic loses [1]. Besides its importance
as patient, the horse is considered one of the most
suitable animal models of musculoskeletal pathologies,
conferring to this species a huge importance for studying
cell-based therapies for orthopedic diseases [2].
Therapeutic potential of mesenchymal stem cells
(MSCs) is mainly attributed to their immunomodulatory
properties, which are induced by exposure to an inflam-
matory environment [3]. Priming MSCs by proinflam-
matory cytokines in vitro may increase their regulatory
effect in vivo [4]. However, this strategy may also raise
MSC immunogenicity because of induced expression of
major histocompatibility complex (MHC), thus poten-
tially limiting the allogeneic administration [5] specially
whether the development of immune memory mecha-
nisms would limit repeated administration [6], which
has been suggested to improve their therapeutic effectivity
provided the limited effect of MSCs in the long term,
especially the allogeneic ones [7].
Antibody production after allogeneic MSC administra-
tion has been reported in several species such as Rhesus
Macaque [8], baboon [9], mouse [6], rat [10], pig [11, 12],
and very recently, in the horse [13–15]. In rhesus ma-
caques, the degree of MHC-mismatching between donor
and recipient can affect the magnitude and type of the
allo-immune response [8]. In horses, antibodies are specif-
ically produced against the haplotype of the equine
leukocyte antigen (ELA) of the donor when the recipient
is ELA-mismatched, but not if donor and recipient are
ELA-matched [13, 14]. This finding is of huge relevance,
but clinical implications are yet unknown since these
studies were conducted in healthy animals and the route
of administration was intradermic, which is not relevant
for clinical application. Another study detected antibody
production in almost 40% of horses receiving allogeneic
MSCs by different routes (intravenous, intraarterial, intra-
tendinous and intraocular), but ELA haplotypes were not
accounted [15]. Furthermore, full match or full mismatch
has been assessed [13, 14], but semi-allogeneic scenario
(halfmatched, i.e., one out of two haplotypes shared) was
not evaluated and it could result in a more realistic sce-
nario for clinical application [14].
In a previous study of our group, we assessed the re-
peated intraarticular (IA) administration of pooled allo-
geneic MSCs, both unstimulated (MSC-naïve) and primed
with proinflammatory cytokines (MSC-primed) in a
chemically induced (Amphotericin B IA injection) osteo-
arthritis (OA) equine model [16]. In this study, we ob-
served beneficial effects of both treatments especially at
the short term, but limited for the longer term. Further-
more, second MSC-primed administration led to a slight
and transient local inflammatory reaction that was not ob-
served after first injection, neither after any MSC-naïve
administration [16]. These findings led us to hypothesize
that, first, immune memory might have been developed
thus limiting the duration of therapeutic effects, and sec-
ond, that MSC-primed cells would be more intensively
targeted because of their increased MHC expression [17].
Therefore, we conducted the present study aimed at asses-
sing the production of allo-antibodies after allogeneic
MSC administration by using stored samples from the
previous study. The goal of the current study is to gain
insight into humoral responses against allogeneic MSCs in
a clinically relevant scenario that included an administra-
tion route not previously assessed (IA), pathologic condi-
tion (OA-model), repeated administration, use of both
unstimulated and primed MSCs, and halfmatching for
ELA haplotypes between donors and receptors.
Methods
Study design
Samples came from a previous experiment in which
all procedures were carried out under Project License
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(PI 31/11) approved by the Ethic Committee for
Animal Experiments from the University of Zaragoza
according to the Spanish Policy for Animal Protection
RD53/2013, which meets the European Union Direct-
ive 2010/63. First, ELA haplotypes of donors (n = 4)
and recipients (n = 7 recipients of MSC-naïve, n = 7
recipients of MSC-primed) of our previous study
using IA administration of allogeneic MSCs were
studied to assess the matching degree among them
and select donor-recipient combinations, also based
on sample availability: among the four donors, one
was selected; among the seven MSC-naïve recipients,
four were selected (all mismatched with the donor
tested: group naïve-mismatched recipients); among
the seven MSC-primed recipients, six were selected
(three halfmatched with the donor: group primed-
halfmatched recipients; and three mismatched with
donor: group primed-mismatched recipients). Second,
two-stage microcytotoxicity assays were carried out by
mixing serially collected sera from selected recipients
(potentially containing antibodies anti-ELA; neat, 1:2
and 1:16 diluted) and target cells with the ELA haplotypes
of the donor selected (peripheral blood lymphocytes
[PBLs], MSC-naïve, MSC-primed; whose expression of
MHC types I and II was assessed by flow cytometry).
Subsequently, rabbit complement was added and eosin
Y dye exclusion was used to determine cell death per-
centage. Time-points selected were as follows: T0 (pre-
administration of MSCs), T1 (1 week after first MSC
administration), T2 (3 weeks after first MSC adminis-
tration; just before the second MSC administration), T3
(1 week after second MSC administration) and T4 (90
days after second MSC administration). Variables of the
study are summarized in Table 1, and the study design
is outlined in Fig. 1.
Determination of ELA haplotypes
Genomic DNA was extracted from frozen samples
(− 80°) of synovial fluid (SF) of all the 18 animals
enrolled in the previous study (Shetland ponies, geld-
ings, 3–7 years, 100–165 kg) using the Quick-gDNA™
Miniprep Kit (Zymo Research) according to the manufac-
turer’s instructions. Horses were genotyped using a panel
of 10 highly polymorphic intra-MHC microsatellites previ-
ously validated [18] that included the following markers:
COR110, COR112, COR113, COR114, UM011 [19],
UMNJH-38, ABGe9019, UMNe65, ABGe9030, and
EQMHC1 [20]. Dr. Antzack and Dr. Miller (Cornell
University) kindly provided DNA samples of known hap-
lotypes analyzed in their laboratory to be used as reference
samples to correctly assign fragment lengths. Fluores-
cently labeled primers were purchased from Invitrogen
using the sequences previously published (Table 2).
Two multiplex polymerase chain reactions (PCR) were
used for amplification: PCR 1 included COR110,
COR112, COR114, and UM011 and PCR 2 included
UMNJH-38, ABGe9019, UMNe65, ABGe9030, and
EQMHC1. The marker COR113 was separately assayed.
Each PCR mix contained 3 μL of 2× PCR Master-mix,
0.6 μL 5× Q-solution, 0.5 μL of primers mix (equal vol-
umes of each one) and 0.9 μL RNAse-free water (Qiagen
Multiplex PCR Kit, Qiagen) making a total volume of
5 μL per sample; 1 μL DNA was used for each reaction.
Amplification protocol consisted of one cycle of 95 °C
Table 1 Summary and description of the variables of the study
Donor Recipients
ELA haplotypes Target cells Group ELA
haplotypes




TNFα and 5 ng/ml IFNγ
for 12 h)
Naïve-mismatched:
• Injected with MSC-naïve
• ELA-mismatched with donor
(0/2 haplotypes shared)





T0 = pre-administration of MSCs
T1 = 1 week after 1st MSC administration
T2 = 3 weeks after 1st MSC administration
(just before 2nd administration)
T3 = 1 week after 2nd MSC administration






• Injected with MSC-primed
• ELA-halfmatched with donor
(1/2 haplotypes shared)





• Injected with MSC-primed
• ELA-mismatched with donor
(0/2 haplotypes shared)




ELA haplotypes of the donor selected and type of target cells; groups of recipients according to MSCs received and their haplotypes (when possible, sharing of
one haplotype among recipients was used as criteria to select more homogeneous groups: naïve-mismatched recipients all shared the haplotype ZAR01; primed-
halfmatched recipients shared the haplotype ZAR07 among them and with the donor - one of the recipients presented the variation ZAR07a; two primed-
mismatched recipients shared the haplotype ZAR03 and the other one did not share any haplotype); time-points at which sera was collected from recipients and
sera dilutions assessed. MSCs mesenchymal stem cells, ELA equine leukocyte antigen, TNFα tumor necrosis factor alpha, IFNɣ interferon gamma, T time, PBL
peripheral blood lymphocyte. 1PBLs were obtained from a different horse but with the same ELA haplotypes than the donor selected
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15′, followed by 30 cycles of 95 °C 30″, 58 °C 1′ and
72 °C 1′, and one cycle of 72 °C 30′ for final extension.
Fragment analysis was performed by mixing 2 μL of
PCR product (diluted 1:5 in water) with 12 μL Hi-Di™
formamide (Applied Biosystems) and 0.3 μL GeneScan™-
500 LIZ™ Size Standard (Applied Biosystems). Electro-
phoresis of the samples was carried out on an ABI 3130
Genetic Analyzer (Applied Biosystems), and fragment
lengths were analyzed with the GeneMapper® v3.7 soft-
ware (Applied Biosystems), using reference samples as
aforementioned.
Rationale for selection of donor-recipient combinations
To perform microcytotoxicity assays, three types of tar-
get cells were used: PBLs, MSC-naïve and MSC-primed.
Since high viability of target cells for microcytotoxicity
assays is required [13], cryopreserved MSCs from the
selected donor were thawed and expanded to ensure
high viability of the cells. However, cryopreserved PBLs
were not available and, furthermore, their viability after
freezing might have been compromised [21] so fresh
PBLs were needed. Provided donors of our previous
study were enrolled as control group in that study, these
animals were also euthanized at the end of the study so
it was not possible to obtain fresh blood from the exact
same donors. Therefore, other animals from the live-
stock of the donors were analyzed to find animals with
the same ELA haplotypes. One of the tested animals
presented the two same ELA haplotypes than one of the
donors, so fresh PBLs were obtained from this animal
under signed owner’s consent. Because of this limitation,
this was the only donor that we could assess.
Based on the ELA haplotypes of the selected donor,
recipients were chosen following two criteria: first,
Fig. 1 Schematic representation of the study design. From all the animals of the previous study, one donor (black), four recipients of MSC-naïve
(all mismatched, dark gray), and six recipients of MSC-primed (three halfmatched, black; three mismatched, dark gray) were selected to assess
humoral response against allogeneic mesenchymal stem cells (MSCs) based on their equine leukocyte antigen (ELA) haplotypes. Peripheral blood
lymphocytes (PBLs), unstimulated MSCs (MSC-naïve), and MSCs pre-stimulated with tumor necrosis factor alpha and interferon gamma (MSC-
primed) of the same ELA haplotype than the donor were used as target cells. Sera collected from the selected recipients at different time-points
(T0, pre-administration of corresponding MSCs; T1, 1 week after first MSC administration; T2, 3 weeks after first MSC administration—just before
the second MSC administration; T3, 1 week after second MSC administration; T4, 90 days after second MSC administration) were tested neat, 1:2
and 1:16 diluted against all the three types of target cells using two-stage microcytotoxicity assays
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matching degree regarding donor; second, matching
degree among recipients within the same group. This
approach was established to take into account the rela-
tionship between donor and recipients (fully or partially
mismatched) and to try to establish recipient groups as
homogeneous as possible (preferably sharing at least one
haplotype within the group). Haplotypes assigned to the
animals selected for this study are presented in Table 1
to clarify the rational choice and grouping of animals.
Preparation of target cells for microcytotoxicity assays
Peripheral blood lymphocytes were isolated using the
carbonyl iron granulocyte depletion method followed by
density gradient centrifugation with Ficoll as previously
described [13]. Briefly, blood was collected via jugular
venipuncture into sterile blood collection tubes with
170 units of lithium heparin (BD) and plasma was
allowed to separate for 20′ at room temperature (RT).
Plasma was collected and incubated with carbonyl iron
(Sigma-Aldrich) in agitation for 30′ at 37 °C. Then,
carbonyl iron was placed in the bottom of the tubes by
using a magnet, and supernatant was collected and cen-
trifuged 310g 10′. The cellular pellet was resuspended in
PBS (Gibco) and overlayed on Lymphoprep (Atom).
After 690g 15′ centrifugation, cell lay was recovered and
washed with PBS. This isolation technique has been
reported to provide enriched lymphocyte population
(95–99%) and has been widely used in related research
[13, 14, 22]. Cells were counted in a hemocytometer
chamber and viability was calculated by using Trypan Blue
0.4% dye exclusion. Concentration was adjusted to 3 × 106
live cells/mL to be used immediately afterwards for micro-
cytotoxicity assays.
Frozen BM-MSCs from selected donor at passage 3
were thawed and expanded at 37 °C 5% CO2 in culture
medium consisting of low glucose Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 2 mM L-glutamine, 0.1 mg/mL
streptomycin and 100 U/mL penicillin (all from Sigma-
Aldrich). Cells from this donor were characterized as
MSCs in a previous study [17]. Four days before per-
forming microcytotoxicity assays, serum component of
the medium was changed by 5% FBS and 5% equine
serum of the same ELA haplotype than the MSCs (i.e.,
from PBLs’ donor). After 48 h, medium was replaced by
a new one containing only 10% equine serum during
additional 48 h. To obtain MSC-primed, BM-MSCs were
exposed to 5 ng/mL of TNFα and 5 ng/mL of IFNγ (both
from R&D Systems) (added to fresh medium also
containing 10% equine serum) during 12 h [16] before
conducting microcytotoxicity. Naïve (unstimulated) and
primed BM-MSCs were detached from plastic with
0.25% trypsin-EDTA (Sigma-Aldrich) and washed in
PBS. Counting and viability calculation were performed
Table 2 Primers used for amplification of horse intra-MHC microsatellites
Locus Dye Primer sequence Allele range (bp) Reference
MHC Class I UMNJH-38 F′ FAM TGTGTGTGCACCTGTCCTTT 156–165 Sadeghi et al., 2018 [18]
R′ GATGGGAGGGAATGAGGAAT
COR110 F′ TTTGGTCTTTGCAGGTATGG 194–221 Tseng et al., 2010 [19]
R′ VIC TCTCCCTTCCTCTTTGTTCC
MHC Class III ABGe 9019 F′ FAM CTGAGAGAGACAGCATTTGTGG 297–320 Sadeghi et al., 2018 [18]
R′ GAAAGGTGTCTCCATTCTTGCT
UNMe65 F′ AT550 (NED) TCGCAAAACCCACAGACTAC 247–269 Sadeghi et al., 2018 [18]
R′ TTCTCCTTTCCTTCCACTCC
MHC Class II ABGe 9030 F′ AT565 (PET) CCAGCAGACCTGCAAGAGTA 205–221 Sadeghi et al., 2018 [18]
R′ AGCATGAGAGCCATGAAGGT
EQMHC1 F′ AT532 (VIC) ATGCATACCGGGAAAGACAG 180–196 Sadeghi et al., 2018 [18]
R′ AGAGACTTCAGTCTCTGTGGTG
COR112 F′ TTACCTGGTTATTGGTTATTTGG 236–268 Tseng et al., 2010 [19]
R′ NED TCACCCACTAAATCTCAAATCC
COR113 F′ TGTTTAGAACTCGCCAGGAG 260–276 Tseng et al., 2010 [19]
R′ FAM TCATCAGTTCCTTGCCTAGC
UM011 F′ TGAAAGTAGAAAGGGATGTGG 165–180 Tseng et al., 2010 [19]
R′ FAM TCTCAGAGCAGAAGTCCCTG
COR114 F′ TCAAAATCCACACTCCCTTC 234–255 Tseng et al., 2010 [19]
R’ PET TCCATAAAGAGTGGGACACTG
Primers (F′, forward; R′, reverse), dye, sequence, allele range (base pair) and reference
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as aforementioned for PBLs. Viability of all the three
types of target cells (PBLs, MSC-naïve, and MSC-
primed) was > 94%. Previous reports of our group
showed appropriate viability of MSCs after inflammatory
priming under these conditions [17]. Cell concentration
was adjusted to 1 × 106 cells/mL in PBS to assay micro-
cytotoxicity immediately after. An aliquot of both MSC-
naïve and MSC-primed was used for flow cytometric
analysis.
MHC-I and MHC-II analysis by flow cytometry
Surface expression of MHC-I and MHC-II was studied
by flow cytometry in both MSC-naïve and MSC-primed
since inflammatory exposure can induce changes in
MHC expression. Methodology followed and antibody
suitability was previously described [23]. Briefly, the cells
were suspended in PBS/2 mM EDTA at 106 cells/ml and
aliquots of 50 μl were transferred to FACS tubes and
incubated 15′ at 4 °C in the dark with monoclonal
antibodies anti-HLA-ABC-FITC (Beckman Coulter) and
HLA-DR-APC (Immunostep). Subsequently, cells were
washed with PBS and diluted in 500 μl of PBS/2 mM
EDTA for analysis in the flow cytometer (FACSARIA,
BD Biosciences). Sytox Blue was used to gate live cells.
Data were analyzed with FACSDIVA 5.0.1 software.
Two-stage microcytotoxicity assays
The standard two-stage microcytotoxicity dye exclusion
assay was carried out to detect cytotoxic antibodies as
previously described [13, 14] using MSC-naïve and
MSC-primed as target cells in addition to PBLs. The
three types of target cells were assayed against sera (neat,
1:2 and 1:16 diluted) from a total of 10 recipients and 5
time-points as stated in the Study Design. Serum of the
same ELA haplotype than MSC donor (i.e., from PBL
donor) was used neat as negative control. As positive
control, serum from one of the animals in the previous
study that was not included in the current one was used.
To select this positive control, sera from the two animals
that showed stronger local reaction after MSC-primed
administration (collected 1 week after second injection)
were tested against PBLs and one antisera was selected
based on providing > 80% of cell death. Frozen sera from
the previous in vivo study were thawed, centrifuged 12,
000g 10′ at 4 °C, and diluted in natural horse serum
(Pan-Biotech). One microliter of corresponding serum
was incubated with 1 μL of corresponding target cell
suspension in Terasaki plates (One Lambda) under min-
eral oil (Sigma-Aldrich) during 30′ at RT. Subsequently,
5 μL of rabbit complement (One Lambda) was added
and plates were incubated for 1 h RT. Then, 2 μL of 5%
Eosin Y dye (Sigma-Aldrich) were added to each well
and after 5′ cells were fixed with 5 μL/well of 10%
formalin (Sigma-Aldrich, pH 7.2–7.4). Two technical
replicates were performed for each condition (type of
target cell, recipient, time, and serum dilution) and con-
trols (positive and negative). The plates were refrigerated
and the percentage of dead cells was assessed within 24
h by the two first authors (LB and AC) using a phase-
contrast (× 10 magnification) Leica inverted microscope
(live cells are refringent and rounded; dead cells are
dark, flat and irregular) and following the scoring system
described by Berglund and Schnabel [13] (score 1 < 10%,
score 2 10–19%, score 4 20–49%, score 6 50–80%, score
8 81–100%). According to these authors, scores of 6 or
higher (> 50% cell death) and scores of 2 or lower (< 20%
cell death) in neat serum were considered to reflect sig-
nificant and non-significant presence of allo-antibodies
in sera, respectively. The average cytotoxicity score was
calculated for each condition and used for statistical
analysis.
Statistical analysis
Statistical analysis was carried out with the SPSS 20.0
software (SPSS, Inc.). Interrater agreement was calcu-
lated with Cronbach’s alpha for each type of target cells
(PBLs, α = 0.966; MSC-naïve, α = 0.970; MSC-primed,
α = 0.944), and thus, mean scores were calculated and
used for subsequent statistical analysis. Descriptive ana-
lysis was performed by calculating the overall percentage
of animals with scores in neat sera over 6 (considered as
significant antibody production) and below 2 (considered
as non-significant antibody production) within each re-
cipient group. Analytical statistics were performed to
check differences in scores depending on the different
study variables. The variables were “type of receptor”
(three categories: naïve-mismatched, primed-mismatched,
primed-halfmatched), “type of target cells” (three categor-
ies: PBLs, MSC-naïve, MSC-primed), “time-point” (five
categories: T0, T1, T2, T3, T4) and “score” (three categor-
ies: score for neat sera, score for 1:2 diluted sera, score for
1:16 diluted sera). “Score” was set as the dependent vari-
able and each other variable as factor to study differences
as follows: (1) differences along time within each group of
recipients for each type of target cells, (2) differences
among types of target cells at each time-point within each
group of recipients, (3) differences among recipient groups
for each type of target cell at each time-point. One-way
ANOVA was performed with Bonferroni or Games-
Howell as post hoc, assessing the homogeneity of vari-
ances by Levene’s test. Significance level was set at p <
0.05 for all analysis.
Results
Assignation of ELA haplotypes
All of the 18 animals enrolled in the previous in vivo
study were heterozygotes for ELA haplotype. Since
familiar relationship among animals was unknown and
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none of the animals was homozygote for all the markers,
haplotypes could only be assigned provisionally. A total
of new 22 provisional haplotypes were found in 17
animals involved in the previous in vivo study, whereas
one animal could not be assigned with any haplotype.
None of the haplotypes observed in this population was
previously described [18, 24]. Further detailed informa-
tion about ELA microsatellite typing is available in
Additional file 1.
MHC-I and MHC-II surface expression
Percentage of MHC-I positive cells was 0.9% for MSC-
naïve and 74.2% for MSC-primed. For MHC-II, 0.2% of
MSC-naïve were positive whereas 24.4% of MSC-primed
expressed MHC-II. These results corroborated the in-
creased expression of both MHC type I and II in MSC-
primed used as target cells in microcytotoxicity assays.
Overall descriptive analysis of allo-antibody production
After IA administration of allogeneic MSCs—naïve or
primed—regardless of the ELA matching degree (half-
matched or mismatched), cytotoxic antibodies were pro-
duced. Mean scores in neat sera were below 6 in all the
conditions (recipient group, type of target cell and time)
(Fig. 2a–c). Pre-existing antibodies were not detected; all
samples were scored as < 2 at T0 except for two recipi-
ents of MSC-naïve, which were assigned > 2 but < 6.
These animals might have had pre-existing antibodies,
for example from a previous transfusion, since their
whole previous medical record is unknown. However,
we decided to maintain these animals in the study design
since their sera scores kept below 6 at all the posterior
times, thus considering that an accelerated humoral re-
sponse by previous exposure was unlikely.
Taking into account all the time-points and consider-
ing overall the different combinations of neat sera and
target cells, 18.75% of sera samples from naïve-mis-
matched recipients, 5.6% from primed-halfmatched, and
5.6% from primed-mismatched groups showed a score >
6. On the other hand, the percentage of sera samples
scored as < 2 was 12.5% for naïve recipients, 13.9% for
primed-halfmatched recipients, and 22.2% for primed-
mismatched recipients.
Allo-antibody production along the time: primary and
secondary humoral response
Along all the time-points assessed, changes in sera
scores when incubated with PBLs were not statistically
significant, neither neat or at any dilution. These scores
followed the same trend when sera were incubated with
MSCs—naïve or primed—as target cells, but observing
significant changes along the time (Fig. 2). For the sake
of clarity, in this section, time evolution will be pre-
sented for each recipient group regardless of the type of
MSCs targeted, and differences between target cells will
be presented in the next section. Nevertheless, it is
worth mentioning that in naïve-mismatched recipients
most of the significant differences along time were found
when using MSC-primed as target cells. However, the
opposite was observed in both mismatched and half-
matched MSC-primed recipients, in which most of the
significant changes were observed when using MSC-
naïve in the microcytotoxicity assays.
Scores from neat sera in the three recipient groups sig-
nificantly increased over T0 at T2, T3, and T4, and in
naïve-mismatched and primed-halfmatched recipients also
at T1 (Fig. 2a–c). In naïve-mismatched (p < 0.01, Fig. 2a)
and primed-halfmatched (p < 0.001, Fig. 2b) recipients,
mean scores peaked at T2 (3 weeks after first injection),
whereas in primed-mismatched recipients maximum
mean values were observed at T1 despite no statistical sig-
nificance (Fig. 2c). One week after second injection (T3),
scores in naïve-mismatched and primed-halfmatched re-
cipients diminished, only significantly over the previous
time-point (T2) in primed-halfmatched recipients (p <
0.05, Fig. 2b). On the other hand, primed-mismatched re-
cipients increased mean scores at T3 (p < 0.01, Fig. 2c). At
T4 (90 days after second injection), scores increased again
in naïve-mismatched recipients (p < 0.001 over T0, Fig. 2a).
However, in primed-halfmatched recipients, scores at T4
remained higher than at T0 (p < 0.05) but significantly de-
creased over T2 (p < 0.05) (Fig. 2b), being the only group
that significantly diminished scores after MSC re-
exposure. Scores at T4 in primed-mismatched recipients
diminished but were maintained significantly higher over
T0 (p < 0.01) (Fig. 2c).
Serial dilutions of sera followed the same trend in the
three groups of recipients with lower mean scores. Scores
in 1:2 and 1:16 diluted sera from naïve-mismatched recipi-
ents were significantly increased over T0 along all time-
points (Fig. 2d, g), as well as with neat sera. On the other
hand, only few significant differences were observed in di-
luted sera from recipients of MSC-primed. In primed-
halfmatched recipients, scores at T2 significantly increased
over T0 in 1:2 diluted (p < 0.5) (Fig. 2e) and no significant
differences along time were observed for 1:16 diluted sera
(Fig. 2h). In the primed-mismatched group, significant in-
crease over T0 was found at T3 in 1:2 (p < 0.05) and 1:16
(p < 0.05) diluted sera (Fig. 2f), plus at T4 in 1:16 dilution
(p < 0.05) (Fig. 2i).
Summarizing, both primary and secondary humoral
responses were detected in mismatched recipients of
MSC-naïve and MSC-primed, the second ones tending
towards a faster development of antibody production.
On the other hand, secondary response was not appar-
ent in halfmatched recipients of MSC-primed and even
a significant decrease in cytotoxic scores was noticed
after re-exposure.
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Cytotoxicity of allo-antibodies on different target cells
When analyzing cytotoxicity against the different types
of target cells, it was observed a trend towards higher
percentage of cell death in MSC-primed compared to
PBLs, finding some punctual significant differences only
in 1:2 and 1:16 diluted sera but not in neat sera. Specific-
ally, MSC-primed were significantly more targeted than
PBLs when exposed to sera (dilution 1:16) from naïve-
mismatched recipients at T3 (Fig. 2g) and from primed-
mismatched recipients at T1 (dilution 1:2, p < 0.05,
Fig. 2f; dilution 1:16, p < 0.01, Fig. 2i).
Allo-antibody production among recipients: effect of MHC
matching (mismatching or halfmatching) and type of
MSCs received (naïve or primed)
When comparing cytotoxic scores between the three
recipient groups at each time-point, an overall trend
towards lower scores in sera from MSC-primed re-
cipients (both halfmatched and mismatched) was
found. Statistically significant differences were only
punctually observed for different target cells, times,
and sera dilution (Additional file 2).
Discussion
The results of this study corroborate the production of
allo-antibodies with cytotoxic capacity directed against
the MHC of administered allogeneic MSCs. This is the
first study in the equine species reporting humoral re-
sponse against allogeneic MSCs repeatedly IA adminis-
tered in OA joints and also taking into account partial
MHC compatibility and the role of proinflammatory
MSC priming.
Nevertheless, this study presents some limitations that
must be considered before discussing the results. First,
halfmatched recipients of MSC-naïve could not be
assessed neither fully matched donor-recipients could be
used as control, since the matching degree between do-
nors and recipients was not set up in the original study.
Nevertheless, previous studies have reported the lack of
immune response when donor and recipient are ELA-
Fig. 2 Evolution of cytotoxic scores along the time in each recipient group comparing different types of target cells. Mean ± S.E.M. of
cytotoxic scores (Y axis) assigned to neat sera (top row; a, b, c), 1:2 diluted sera (middle row; d, e, f), and 1:16 diluted sera (bottom row;
g, h, i) from mismatched recipients of MSC-naïve (left column; a, d, g) and MSC-primed, halfmatched (middle column; b, e, h) and
mismatched (right column; c, f, i), along the time (X axis; T0, pre-administration of corresponding MSCs; T1, 1 week after first MSC
administration; T2, 3 weeks after first MSC administration—just before the second MSC administration; T3, 1 week after second MSC
administration; T4, 90 days after second MSC administration), when assayed against different target cells: PBLs, peripheral blood
lymphocytes (white bar, control); MSC-naïve, unstimulated mesenchymal stem cells (light gray bar); MSC-primed, mesenchymal stem cells
pre-stimulated with tumor necrosis factor alpha and interferon gamma (dark gray bar). Asterisks (*) point out statistically significant
differences among time-points (* = p < 0.05, ** = p < 0.01, *** = p < 0.001) and hashes (#) indicate significant differences between different
target cells at one particular time (# = p < 0.05, ## = p < 0.01)
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matched, both in vitro [22] and in vivo [13, 14]. Second,
ELA haplotypes could only be provisionally assigned due
to the absence of homozygous or family-related animals in
the study. Third, MSCs from four donors were adminis-
tered as a pool in the previous in vivo study [16] but allo-
antibody production could only be studied against ELA
haplotypes of one of the donors, yet cross-reactivity of
anti-ELA antibodies cannot be excluded [14].
In this study, antibody peak production was observed
between 1 and 3 weeks after first administration of
allogeneic MSCs. Similarly, the first study reporting allo-
antibody production against MHC-mismatched MSCs in
the equine species [14] showed a peak in antibody pro-
duction between 2 and 3 weeks after administration in 4
out of the 6 horses assessed. In the remaining two recip-
ients, humoral response was weak so a second adminis-
tration was performed. In one of them, slight response
was observed whereas the other horse did not respond
to re-exposure. Therefore, considerable variability could
be expected between recipients in terms of humoral
response against allo-MSCs [14]. A continuation of that
study tested the sera from the four reactive horses with
MSCs as target cells, showing that microcytotoxicity
against these cells also increased from 1 to 3 weeks post-
administration [13].
In the aforementioned studies, effect of re-injection in
animals already showing a primary humoral response
was not tested and only intradermal route was assessed.
There is a third study on antibodies against equine allo-
MSCs that assessed different routes of administration
and repeated doses of allogeneic cells of unknown ELA
[15]. This study found that almost 40% of horses that re-
ceived allogeneic MSCs by different routes developed a
humoral response, with more marked response in ani-
mals injected intratendinous, which also received higher
number of administrations (five injections). However, in
this study, the specificity of the antibodies against MHC
was not tested and only the end-point was assessed, but
not the evolution along the time of the humoral re-
sponse and the influence of each administration. There-
fore, studies on the evolution of humoral response along
the time and the effect of repeated administration are
needed in horses.
In our study, evolution of cytotoxic scores along the
time in sera from different recipients suggested the
development of both primary and secondary (after first
and second MSC injection, respectively) humoral re-
sponses. This dynamic was observed in mismatched re-
cipients of both MSC-naïve and MSC-primed, the
second ones apparently showing faster development of
antibody production. However, secondary response was
not apparent in halfmatched recipients after second in-
jection of MSC-primed. It could be hypothesized that
when recipients of MSC-primed were partially matched
with the donor, primary humoral response would be
produced similarly to mismatched recipients of MSC-
naïve, but secondary humoral response would be attenu-
ated after re-exposure. It should also be considered that
this apparent lack of secondary response may also be
due to rapid elimination of MSC-primed after second in-
jection by already existing antibodies, having no time to
produce a secondary response [14]. However, animals
that also received MSC-primed but were completely
mismatched with the donor did develop a secondary
humoral response, suggesting that MSC-primed would
not be so rapidly removed.
Only few studies in other species have also assessed
the effect on the humoral response of priming MSCs
with IFNγ, finding no differences regarding antibody
production compared to unstimulated ones [10], or find-
ing them only after multiple injection of allogeneic
primed MSCs [12]. We hypothesize that increased im-
munomodulatory activity of MSC-primed [17] together
with partial matching for MHC might have attenuated
the development of a secondary humoral response, being
these factors potentially beneficial for allogeneic therapy.
On the other hand, overall trend observed in mis-
matched recipients of MSC-primed suggested faster de-
velopment of both primary and secondary humoral
responses than in the other groups. Faster humoral re-
sponses are associated to previous exposure [11, 25], but
pre-existing antibodies were not found in any animal of
this group. Therefore, it might be hypothesized that
higher MHC expression of MSC-primed would acceler-
ate the humoral response in mismatched recipients,
whereas it might be attenuated in halfmatched ones.
The fact that significant differences along the time
were found in sera from naïve recipients mostly against
MSC-primed as target cells, and vice versa in both
groups of MSC-primed recipients, is an unexpected ob-
servation, but we were unable to attribute a biological
meaning. It is possible that it could be due just to the
lower deviation in scores recorded when using one or
another type of target cell in each group.
Lack of humoral response in animals that received
ELA-matched allogeneic MSCs (2/2 haplotypes shared)
has been previously described [13, 14], but the effect of
partial matching (1/2 haplotypes shared) on antibody de-
velopment was not previously reported in the horse. In
rhesus macaques [8] and humans [26], partial MHC
matching has been accounted as sharing of some al-
leles—but not of complete haplotype—between donor
and recipient, finding a protective effect of partial
matching in rhesus macaques, and no significant effect
in humans. Halfmatching represents a more realistic
clinical scenario, provided that in practice it is difficult
to find donors completely matched with the patient be-
cause of the great variability of ELA haplotypes [18, 19]
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that was also observed in this study even with limited
population. According to our data, partial MHC matching
would not prevent antibody production but might have
attenuated the secondary response after re-exposure.
In this study, average scores tended to be lower than
those previously reported, with less than 11% of all sam-
ples scored above 6. Overall, cytotoxic scores were below
the limit setup for significant response both after first
and second administration of either MSC-naïve or MSC-
primed. Therefore, accordingly to previous reports in
human medicine, the clinical relevance of this immune
reaction for single injection may not be a major concern
[26, 27]. However, this primary humoral response could
compromise the effectiveness and safety of repeated ad-
ministration as transient but significant increase in some
inflammatory parameters were detected in the in vivo
study after the second injection of MSC-primed [16].
Accordingly, a recent study assessing allo-sensitization
after single administration of allogeneic MSCs in
Chron’s disease patients showed generation of donor-
specific antibodies (DSA) just in a proportion of patients,
but those presenting pre-existing immunity were prone
to produce DSA after allogeneic therapy [28].
This discrepancy in the average cytotoxic scores over
prior reports may be the result of different route of ad-
ministration, since previous studies used the intradermal
[14] whereas we assessed IA injection [16]. Because of
the role of the skin as immune organ rich in blood and
lymphatic vessels [29], stronger immune responses
might be expected after intradermic MSC injection,
whereas weak allo-antibody production was also re-
ported in humans receiving IA allogeneic MSCs for knee
OA [26]. The assessment of cytotoxic antibodies locally
in the SF could have provided further information with
this regard, but the limited availability of SF samples
prevented its evaluation. Nevertheless, to the best of our
knowledge, there are no reports on the local assessment
of allo-antibodies after MSC administration.
Whereas recipients of MSC-primed, both mismatched
and halfmatched, tended to produce fewer antibodies
in vivo, these cells tended to be more targeted in the
microcytotoxicity assays in vitro. These two observa-
tions, apparently opposed, might be due to a lower
humoral response produced by MSC-primed after first
injection because of their potentiated immune regulatory
status [17]. However, after second injection, already
formed antibodies would target these cells more easily
because of their increased MHC expression.
Even though it is complex to correlate data from
humoral response with clinical observations in the original
in vivo study, it is worth noting that MSC-primed showed
more capacity in vivo to regulate the inflammatory and
catabolic joint environment at the short term [16], which
might be related with higher capacity to evade the
immune response thus producing fewer antibodies after
first administration as suggested by this study. However,
in the in vivo study, slight and transient local inflamma-
tion was noticed after second injection of MSC-primed,
showing this group significant increase in the carpal
perimeter and non-significant increase in the local
temperature 24 h after re-injection and significant increase
in synovial total white cell count 1 week after re-exposure
that were not detected in the MSC-naïve group [16].
These clinical findings might be associated with targeting
of MSC-primed by the antibodies produced after first in-
jection, based on increased cell death observed when
MSC-primed were used as target cells in microcytotoxicity
assays in the present study. Therefore, even though the
humoral response could be considered as mild based on
cytotoxic scores, the antibody production could have a
clinical impact by compromising the repeated administra-
tion of allogeneic cells, especially the primed ones.
Conclusions
On the one hand, repeated IA injection of allogeneic
MSCs (unstimulated) in mismatched horses resulted in
both primary and secondary humoral responses. On the
other hand, the immunomodulatory profile of MSCs
primed with proinflammatory cytokines might have
helped them to more effectively regulate the inflammation
and to elicit lower primary humoral response when ad-
ministered for the first time. However, if repeatedly
injected, MSC-primed might be more easily targeted by
pre-existing antibodies because of their increased expres-
sion of MHC. Nevertheless, partial compatibility between
donor and recipient may help to avoid this secondary
humoral response after re-exposure to MSC-primed. The
immune response elicited against equine allogeneic MSCs
and the factors influencing it must be further studied to
develop more effective and safer cell therapies.
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